We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Spotlights Innovations and Trends in Clinical Diagnostics and Point-of-Care Testing

By LabMedica International staff writers
Posted on 21 Jul 2023
Print article
Image: The IMMULITE 2000 XPi immunoassay system (Photo courtesy of Siemens)
Image: The IMMULITE 2000 XPi immunoassay system (Photo courtesy of Siemens)

Siemens Healthineers (Erlangen, Germany) is highlighting its newest innovations and trends in clinical diagnostics and point-of-care testing at AACC 2023.

At the Siemens AACC 2023 booth, experts will provide a high-level overview of Atellica Integrated Automation. Powered for workflow and workforce efficiency, the company’s Atellica Solution delivers control and simplicity so labs can drive better outcomes. Experts will also demonstrate how the IMMULITE 2000 XPi immunoassay system can address common challenges faced by specialty laboratories. Providing multiple tests on a single, easy-to-use analyzer, the IMMULITE 2000 XPi immunoassay system makes it simple for labs to scale capabilities without disrupting regular day-to-day operations. It allows consolidation of routine and specialty testing, including allergy, on a single platform in labs with low to medium test volumes. Labs can incorporate specialty testing, including allergy, into routine workloads without interrupting the lab workflow in labs with medium to high test volumes.

Visitors to the Siemens booth at AACC 2023 also had the first view of the newly-launched Atellica CI Analyzer, a compact testing system designed to tackle lab challenges. The Atellica CI Analyzer1 for immunoassay and clinical chemistry testing is the newest addition to Siemens’ Atellica in vitro diagnostics portfolio. The Atellica CI Analyzer makes it possible for both standalone labs and satellite labs of wider health networks to have the same reagents, consumables, and intelligent software as the company's flagship Atellica Solution—now condensed into a 1.9 square meters footprint ideal for smaller laboratories. The Atellica CI Analyzer aims to address labor shortage pain points and drive revenue growth, fostering agility beyond standardization and clinical equivalence.

Siemens is also demonstrating how labs can leverage the power of open connectivity with POC informatics. With its POCcelerator Data Management System, labs can simplify their POCT workflows and dramatically reduce workload for their staff. All patient results, quality controls, operators, reagents, and device data can be collected and reviewed in a clear and structured format in order to comply with regulatory guidelines. In addition, Siemens is demonstrating the utility of its non-invasive tests such as the ELF Test in the NALFD/NASH patient referral pathway, alongside its advancements in VWD diagnostics for improved management of bleeding patients. Among its solutions for critical care testing, Siemens is showcasing its epoc Blood Analysis System that securely delivers critical testing results at the patient-side in less than one minute and connects the entire team, so it doesn’t matter if the laboratory staff and caregivers work in different parts of the hospital.

Related Links:
Siemens Healthineers

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.